Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0VYGGK
ADC Name
BMS-986148
Synonyms
BMS 986148; Mesothelin-ADC
   Click to Show/Hide
Organization
Bristol Myers Squibb Co.
Drug Status
Phase 2
Indication
In total 6 Indication(s)
Gastric cancer [ICD11:2B72]
Phase 2
Non-small cell lung cancer [ICD11:2C25]
Phase 2
Ovarian cancer [ICD11:2C73]
Phase 2
Pancreatic cancer [ICD11:2C10]
Phase 2
Pleural mesothelioma [ICD11:2C26]
Phase 2
Solid tumors [ICD11:2A00-2A0Z|2B50-2F9Z]
Phase 1
Drug-to-Antibody Ratio
3
Structure
Antibody Name
BMS-986021
  Antibody Info 
Antigen Name
Mesothelin (MSLN)
  Antigen Info 
Payload Name
Tubulysin
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Mal-EBE-Mal
  Linker Info 
Conjugate Type
Random conjugation through reduced inter-chain cysteines.
Combination Type
BMT-125961
TTD ID
D03TBD
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 3 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Objective Response Rate (ORR)  NCT02341625
Phase 1/2a
A phase 1/2a study of BMS-986148, a mesothelin directed antibody drug conjugate, in subjects with select advanced solid tumors.
Undisclosed  NCT02341625
Phase 1/2
A phase 1/2a study of BMS-986148, a mesothelin directed antibody drug conjugate, in subjects with select advanced solid tumors.
Undisclosed  NCT02884726
Phase 1
A phase 1 study of the safety and tolerability of BMS 986148 in subjects with advanced and/or metastatic solid tumors.
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Objective Response Rate (ORR)
2.00% (All escalation, BMS-986148 monotherapy)
6.00% (All expansion, BMS-986148 monotherapy)
4.00% (Mesothelioma expansion, BMS-986148 monotherapy)
9.00% (Ovarian expansion)
20.00% (All, BMS-986148 + nivolumab)
23.00% (Mesothelioma, BMS-986148 + nivolumab)
Patients Enrolled
Pleural or peritoneal mesothelioma (except sarcomatoid mesothelioma), ovarian cancer (except mucinous carcinoma), pancreatic cancer, gastric cancer, or non-small cell lung cancer (adenocarcinoma only).
Administration Dosage
BMS-986148 monotherapy (0.1-1.6 mg/kg intravenously (i.v.) every 3 weeks or 0.4 or 0.6 mg/kg i.v. once weekly; n = 96) or BMS-986148 0.8 mg/kg + nivolumab 360 mg i.v. every 3 weeks (n = 30). The primary endpoint was safety and tolerability.
Related Clinical Trial
NCT Number NCT02341625  Clinical Status Phase 1/2a
Clinical Description A phase 1/2a study of BMS-986148, a mesothelin directed antibody drug conjugate, in subjects with select advanced solid tumors.
Primary Endpoint
The MTD and the recommended dose for the part 2 monotherapy expansion is BMS-986148 1.20 mg/kg every 3 weeks dose level. The MTD in the combination expansion cohort is BMS-986148 0.80 mg/kg + nivolumab 360 mg every 3 weeks.
Experiment 2 Reporting the Activity Date of This ADC [2]
Related Clinical Trial
NCT Number NCT02341625  Clinical Status Phase 1/2
Clinical Description A phase 1/2a study of BMS-986148, a mesothelin directed antibody drug conjugate, in subjects with select advanced solid tumors.
Experiment 3 Reporting the Activity Date of This ADC [3]
Related Clinical Trial
NCT Number NCT02884726  Clinical Status Phase 1
Clinical Description A phase 1 study of the safety and tolerability of BMS 986148 in subjects with advanced and/or metastatic solid tumors.
References
Ref 1 Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors. Clin Cancer Res. 2022 Jan 1;28(1):95-105.
Ref 2 A Phase I/IIa Study of BMS-986148, a Mesothelin Directed Antibody Drug Conjugate, in Subjects With Select Advanced Solid Tumors, NCT02341625
Ref 3 A Phase 1 Study of the Safety and Tolerability of BMS 986148 in Subjects With Advanced and/or Metastatic Solid Tumors, NCT02884726

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.